Combination of interferon alpha and ribavirin in the treatment of hepatitis C: implications for the clinical nephrologist

Open Access
Publisher Website
Google Scholar
Abstract
Hepatitis C virus (HCV) infection is very frequent among patients with end-stage renal disease (ESRD). Recent studies have shown that HCV may increase the risk for death in the haemodialysis (HD) population and appears to have a deleterious impact on long-term graft and patient survival among renal transplant recipients [1]. Furthermore, HCV results in a significantly increased risk of kidney allograft failure and death among kidney–pancreas transplant patients.